Trendlyne Blog: , Latest on stock market and finance in India and the world.

Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets

IND

USA

Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding

Biocon Ltd.

07 Aug 2025

361.55

1.53%

Biocon Q1 results: Net profit down 95%, revenue rises 15% to 4,022 cr

Business Standard

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth

Copy LinkShare on

Share on Share on Share on

Biocon Ltd.'s price crossed above 200Day SMA today

Biocon Q1 Results: Profit Slumps 95% Even As Revenue Rises

NDTV Profit | 07 Aug 2025

Lupin Ltd.

07 Aug 2025

1951.10

3.25%

Broker's call: Lupin (Buy)

Business Line

PL Capital

Copy LinkShare on

Share on Share on Share on

Sharekhan released a Buy report for Lupin Ltd. with a price target of 2400.0 on 21 Aug, 2025.

Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price Here's Why

NDTV Profit | 07 Aug 2025 3 more

Lupin shares advance 5% after Q1 results; should you buy in?

Business Standard | 07 Aug 2025

Lupin Q1 Review: Goldman Sachs Remains Neutral, Hikes Target Price

NDTV Profit | 07 Aug 2025

As US tariffs loom, Lupin looks at measures to mitigate impact

Business Line | 06 Aug 2025

Emcure Pharmaceuticals Ltd.

07 Aug 2025

1371.40

0.46%

Emcure Pharmaceuticals posts 41% growth in profit in Q1

Business Line

International business remained a key growth driver, growing 22.1 per cent to 1,106 crore

Copy LinkShare on

Share on Share on Share on

Emcure Pharmaceuticals Ltd. is trading below its 30 day SMA of 1424.7

Emcure Pharma Q1 Results: Net Profit Up 41% At Rs 215 Crore

NDTV Profit | 07 Aug 2025

Lincoln Pharmaceuticals Ltd.

07 Aug 2025

555.45

-0.12%

Lincoln Pharma Q1 Results: Net Profit Rises 17%

NDTV Profit

Lincoln Pharmaceuticals reported a net profit of Rs 27.7 crore for the April-June quarter.

Copy LinkShare on

Share on Share on Share on

Lincoln Pharmaceuticals Ltd.'s price crossed below 50Day SMA today

Lincoln Pharma Q1 results: Profit up 17% to 28 cr, share jumps 8.5%

Business Standard | 07 Aug 2025

Hikal Ltd.

07 Aug 2025

267.90

-0.52%

Smallcap pharma stock hits 52-week low, slips 8% on Q1 loss. Do you own?

Business Standard

Shares of Hikal hit a 52-week low of 281.90, falling 8 per cent on the BSE in Thursday's intra-day trade after the pharma company posted a net loss of 22.4 crore in Q1FY26.

Copy LinkShare on

Share on Share on Share on

Number of FII/FPI investors increased from 92 to 104 in Jun 2025 qtr.

Alembic Pharmaceuticals Ltd.

06 Aug 2025

955.75

1.25%

Alembic Pharma dips 3% post Q1 results; MOFSL retains Neutral, here's why

Business Standard

Alembic Pharma fell around 3.5 per cent to hit an intraday low of 913 on the NSE, after the company reported its June 2025 quarter results

Copy LinkShare on

Share on Share on Share on

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 955.5

Alembic Pharma Q1 Review: Dolat Capital Maintains 'Add', Revises Target Price Here's Why

NDTV Profit | 06 Aug 2025 1 more

Alembic Pharma Q1 net profit rises 14% to 154 crore, revenue up 10%

Business Standard | 05 Aug 2025

Gland Pharma Ltd.

06 Aug 2025

1876.80

0.52%

'Buy' Gland Pharma Shares Maintains Motilal Oswal On Strong Q1 Earnings Growth, Valuation Check Target Price

NDTV Profit

Gland Pharma is fortifying its positioning in the complex injectable space through in-house product development as well as partnerships, adds the brokerage.

Copy LinkShare on

Share on Share on Share on

Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.

Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?

Business Standard | 06 Aug 2025 5 more

Gland Pharma Share Price Surges Over 6% As Jefferies Upgrades Ratings, Hikes Target Price Post Q1 Results

NDTV Profit | 06 Aug 2025

Gland Pharma Q1 Review: Brokerages DividedJefferies Upgrades Rating To Hold, Citi Maintains Sell

NDTV Profit | 06 Aug 2025

Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround

Business Standard | 05 Aug 2025

Gland Pharma Q1FY26 net profit up 50% at 215 cr

Business Line | 05 Aug 2025

Gland Pharma Q1 Results: Profit Surges 50%, Meets Estimates

NDTV Profit | 05 Aug 2025

Eris Lifesciences Ltd.

06 Aug 2025

1779.90

0.50%

'Buy' Eris Lifesciences Shares Maintains PL Capital Post Q1 Results; Revises Target Price

NDTV Profit

Eris maintains revenue growth guidance of 15-20% for FY26E, adds PL Capital

Copy LinkShare on

Share on Share on Share on

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Business Standard | 05 Aug 2025

Aurobindo Pharma Ltd.

06 Aug 2025

USFDA Observation

1034.90

1.24%

Aurobindo Pharma Q1 Results Review: Motilal Oswal Maintains 'Buy' Check Target Price

NDTV Profit

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, subsequently, the stock price, adds the brokerage.

Copy LinkShare on

Share on Share on Share on

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.